Of the 121 affordable units, 61 will be reserved for households earning up to 120% of the area median income (currently $103,200 for a family of three), and 60 will be set aside for households earning up to 80% of the area median income (currently $68,800 for a family of three)
Are branded GLP-1 drugs easier to get covered for weight loss than for diabetes
Your licensed provider can explain what this distinction means for your individual situation
When Long-Term Treatment Is the Right Choice For some, remaining on a maintenance dose of GLP-1 medication makes sense
Proper mixing is not complicated, but doing it wrong costs money
Semaglutide 2.4mg (GLP-1 Agonist): Proven GLP-1 effects (appetite suppression, gastric emptying) Already FDA-approved as Wegovy Established safety profile Cagrilintide 2.4mg (Amylin Analog): Mimics amylin, a hormone co-secreted with insulin Slows gastric emptying through different pathway than GLP-1 Reduces appetite through hindbrain (not hypothalamus) Improves postprandial glucose The Advantage: Leverages proven semaglutide efficacy and safety, adds complementary amylin effects
